Chinese Pharma Advances AI-Discovered Drug to Phase III Trials
96Stats · x · 2026-07-14
A Chinese pharmaceutical company has advanced a lung cancer drug—entirely targeted and molecularly designed by AI—into Phase III clinical trials (involving 320名患者). Additionally, the company invested up to 1.75 亿美元 in developing another brain disease drug based on an AI-identified mechanism. This indicates a shift in Chinese pharma procurement models: moving from simply subscribing to AI software tools to directly purchasing AI-generated biological hypotheses and outcomes.
Related event: AI-Discovered Drug Enters Phase III Trials in China(2 posts)→
More from Research
- Gemma 4 12B visualization shows what the model predicts from video patches — arjunrajlab · 2026-07-21
- Baseten study finds new facts in LLM weights are fragile unless trained from many restatements — alex_verem · 2026-07-21
- Kimi K3 and Fable 5 now look much closer than the old open-vs-closed gap — FinanceYF5 · 2026-07-21
- uv-scripts/ocr returns to the top of Hugging Face datasets with a JSON model picker — vanstriendaniel · 2026-07-21
- DeepSearch-World trains web agents with 420K verifiable QA tasks — HKUST · 2026-07-21
- GigaAM Multilingual targets low-resource Central Asian ASR with 2M hours of audio — ai-sage · 2026-07-21